TW202146024A - 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 - Google Patents

包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 Download PDF

Info

Publication number
TW202146024A
TW202146024A TW110107183A TW110107183A TW202146024A TW 202146024 A TW202146024 A TW 202146024A TW 110107183 A TW110107183 A TW 110107183A TW 110107183 A TW110107183 A TW 110107183A TW 202146024 A TW202146024 A TW 202146024A
Authority
TW
Taiwan
Prior art keywords
cancer
compound
braf
dabrafenib
pharmaceutically acceptable
Prior art date
Application number
TW110107183A
Other languages
English (en)
Chinese (zh)
Inventor
凡瑟莉娜 庫克
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202146024A publication Critical patent/TW202146024A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW110107183A 2020-02-28 2021-02-26 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合 TW202146024A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062983020P 2020-02-28 2020-02-28
US62/983,020 2020-02-28

Publications (1)

Publication Number Publication Date
TW202146024A true TW202146024A (zh) 2021-12-16

Family

ID=76845267

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110107183A TW202146024A (zh) 2020-02-28 2021-02-26 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合

Country Status (9)

Country Link
EP (1) EP4110341A2 (ko)
JP (1) JP2023516155A (ko)
KR (1) KR20220148846A (ko)
CN (1) CN115279374A (ko)
AU (1) AU2021225491A1 (ko)
CA (1) CA3173356A1 (ko)
IL (1) IL295626A (ko)
TW (1) TW202146024A (ko)
WO (1) WO2021171260A2 (ko)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EA201170375A1 (ru) 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
EP2342229A1 (en) 2008-09-12 2011-07-13 ISIS Innovation Limited Pd-1 specific antibodies and uses thereof
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
JP5920929B2 (ja) 2010-03-11 2016-05-18 ユセベ ファルマ ソシエテ アノニム Ｐｄ−１抗体
RU2625034C2 (ru) 2011-04-20 2017-07-11 МЕДИММЬЮН, ЭлЭлСи Антитела и другие молекулы, которые связывают в7-н1 и pd-1
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
RU2723050C2 (ru) 2013-05-02 2020-06-08 Анаптисбайо, Инк. Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1)
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
HRP20221262T1 (hr) 2013-09-13 2022-12-09 Beigene Switzerland Gmbh Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava
US9242996B2 (en) 2013-11-01 2016-01-26 Novartis Ag Aminoheteroaryl benzamides as kinase inhibitors
PL3081576T3 (pl) 2013-12-12 2020-03-31 Shanghai Hengrui Pharmaceutical Co., Ltd. Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JP7114575B2 (ja) * 2016-09-19 2022-08-08 ノバルティス アーゲー Ｒａｆ阻害剤及びｅｒｋ阻害剤を含む治療用組合せ
WO2019186488A1 (en) * 2018-03-30 2019-10-03 Novartis Ag A triple pharmaceutical combination comprising dabrafenib, trametinib and an erk inhibitor

Also Published As

Publication number Publication date
CN115279374A (zh) 2022-11-01
WO2021171260A3 (en) 2021-10-07
IL295626A (en) 2022-10-01
WO2021171260A2 (en) 2021-09-02
JP2023516155A (ja) 2023-04-18
CA3173356A1 (en) 2021-09-02
EP4110341A2 (en) 2023-01-04
AU2021225491A1 (en) 2022-10-20
KR20220148846A (ko) 2022-11-07

Similar Documents

Publication Publication Date Title
TWI831916B (zh) 包含tno155和瑞博西尼之藥物組合
TW202146021A (zh) 包含達拉菲尼、erk抑制劑和shp2抑制劑之三重藥物組合
WO2013139724A1 (en) Combination therapy (vemrufenib and a mdm2 inhibitor) for the treatment proliferative disorders
TW202313041A (zh) 包含達拉菲尼、曲美替尼和shp2抑制劑之三重藥物組合
US20210300921A1 (en) Ep4 inhibitors and synthesis thereof
CN114072205A (zh) 用tie-2激活剂治疗高血压的方法
US11413284B2 (en) Protein kinase C inhibitors for treatment of uveal melanoma
TW202146024A (zh) 包含達拉菲尼、erk抑制劑和raf抑制劑或pd-1抑制劑之三重藥物組合
CN111936141A (zh) 包含达拉菲尼、曲美替尼和erk抑制剂的三重药物组合
AU2021260982B2 (en) Dosing regimen for treating a disease modulated by CSF-1R
AU2020351324B2 (en) Use of an MDM2 inhibitor for the treatment of myelofibrosis
TW202416986A (zh) 使用ｕｌｋ抑制劑治療病症之方法
WO2024050351A1 (en) Combination of dcc-3116 and mapkap pathway inhibitors for use in the treatment of cancer
TW202404586A (zh) 癌症的治療或預防用藥物